Nuclear Medicine Advances Span Prostate Cancer, Stroke, and Diabetes Imaging

A wave of new research published ahead of print in The Journal of Nuclear Medicine is offering a glimpse of where molecular imaging and theranostics are headed, from sharper ways to see prostate cancer and breast cancer metastases to tracers that reveal cellular stress after stroke and track the slow loss of insulin-producing cells in type 1 diabetes. The studies, released on October 9, 2026, by the Society of Nuclear Medicine and Molecular Imaging, span the full arc of the field: new paired imaging-and-therapy agents, enzyme-based tricks to sharpen image contrast, patient-centered questions about scan quality, and long-term safety data on radiopharmaceutical treatments. Together they illustrate how nuclear medicine continues to push toward imaging that is more sensitive, more specific, and more closely matched to the biology of each patient’s disease.

Among the most technically striking reports is a paired imaging and treatment approach for prostate cancer built on compounds that target PSMA, or prostate-specific membrane antigen, a protein abundantly expressed on prostate cancer cells. The strategy pairs a diagnostic imaging agent with a therapeutic compound designed to bind the same molecular target, an approach at the heart of theranostics, the practice of using matched agents to first visualize a disease target and then deliver radiation to it. In mouse models, the therapeutic agent accumulated in tumors at 2.2 to 3.5 times higher levels than a reference treatment, while producing similar effects on tumor growth. Just as importantly, the imaging agent showed a distribution pattern closely matching that of the therapeutic compound, suggesting it could serve as a reliable preview of where the therapy would travel in the body. That pairing is precisely the logic that makes theranostics attractive: if the diagnostic tracer lights up a tumor, the therapeutic counterpart should follow the same path.

A second study tackled one of the persistent frustrations of molecular imaging: background noise from radioactive material still circulating in the bloodstream. When unbound tracer lingers in the blood, it can wash out the contrast between tumor and surrounding tissue, making small or subtle lesions harder to see. The researchers developed a method that uses enzymes to clear unneeded radioactive material from the circulation after injection. In mice, treatment with the enzyme carboxypeptidase G2 increased the imaging signal from tumors relative to blood by more than 40 percent. The concept relies on a clever chemical design in which the tracer is engineered so that the enzyme can alter it in the blood, accelerating its clearance, while the tracer that has already bound to its cancer target remains intact. The result is a cleaner image in which the tumor stands out more clearly against a quieter background, potentially helping clinicians visualize cancer targets that would otherwise be lost in vascular noise.

Breast cancer imaging also featured prominently in the new releases. Researchers evaluated a new PET tracer that targets nectin-4, a protein found in several cancers, in a pilot study of six patients with breast cancer. The tracer performed similarly to standard imaging for primary tumors and most lymph node metastases, but in some patients it detected more bone and liver metastases than conventional approaches. Because nectin-4 is a recognized target for antibody-drug conjugates in oncology, a PET tracer that maps its expression could eventually help clinicians identify which patients are candidates for such therapies and monitor how the target behaves across different metastatic sites. The pilot study is small, and the authors’ findings will need validation in larger cohorts, but the pattern of detecting additional bone and liver lesions hints at biological information that current standard imaging may miss.

The brain was the focus of another new tracer evaluation, this one designed to detect erythropoietin receptors, which are involved in cellular responses to low oxygen levels. In two animal models of ischemic stroke, the tracer accumulated in damaged brain regions, mapping the territory where tissue is under metabolic stress. Tests of human stroke tissue also showed tracer binding, particularly in areas surrounding the most severely damaged tissue, a distribution known as the penumbra, where cells are endangered but not yet dead. A tracer that can visualize this stressed-but-salvageable tissue in living patients could become a valuable complement to existing stroke imaging, which primarily distinguishes between tissue that is already infarcted and tissue that is perfused. By revealing the molecular signature of hypoxic stress, the tracer could help clinicians and researchers better understand the time course of injury and, potentially, refine patient selection for reperfusion therapies.

Diabetes research took a different imaging angle, using PET/CT to measure insulin-producing beta cells in 26 people with type 1 diabetes. Those diagnosed less than seven years earlier had greater beta-cell mass, larger pancreases, and less pancreatic fat than those living with longer-duration disease. The study also found that beta-cell mass was associated with insulin-producing function, linking what the scanner sees to what the pancreas can still do. The findings carry implications for the design of clinical trials aimed at preserving or regenerating beta cells, since a noninvasive measure of beta-cell mass could serve as an endpoint or a stratification tool. They also add to a growing body of evidence that the pancreas itself changes in type 1 diabetes over time, not only in its endocrine cells but in its overall size and fat content.

Not all of the new work involved new chemistry. A survey of 227 patients undergoing PET/CT examined how people weigh scan quality, duration, comfort, and access when choosing among imaging options. Nearly eight in 10 respondents preferred better-quality images even if the scans took longer, and 80 percent said they were willing to wait more than an hour after tracer injection to obtain them. Most participants reported little or no discomfort during scanning. In an era when imaging protocols are often optimized for scanner throughput, the survey is a reminder that patients themselves frequently prioritize diagnostic confidence over convenience, and that longer acquisition times or longer waits between injection and imaging may be far more acceptable to patients than imaging departments assume.

Pediatric oncology and endocrine imaging each gained a practical refinement. In a study of five children ages 3 to 7 with advanced neuroblastoma, researchers evaluated a new PET tracer targeting somatostatin receptors. The imaging identified 17 cancer lesions with strong contrast between tumors and surrounding tissues, and the scan delivered a low overall radiation dose, an especially important consideration in young children. The results support further evaluation of the approach in pediatric patients, where minimizing radiation exposure while maximizing diagnostic yield is a central design constraint. Separately, a study of 119 patients with primary hyperparathyroidism found that delayed PET/CT imaging performed 60 minutes after injection improved image contrast compared with scans taken at 10 minutes. The delayed protocol changed clinical interpretation in 19.3 percent of cases and revealed a parathyroid adenoma in eight patients whose early scans had been negative, suggesting that simply waiting longer before imaging can meaningfully improve the detection of overactive parathyroid glands.

Finally, the collection included long-view safety data on radiopharmaceutical therapy for advanced prostate cancer. Researchers compared kidney function in patients treated with radiopharmaceutical therapy or chemotherapy and found that kidney function declined similarly in both groups during the first six months. Over longer follow-up, however, the picture diverged by baseline status: declines were more pronounced in patients with preexisting chronic kidney disease, while those with initially preserved kidney function showed no significant change. That distinction matters for clinicians weighing radioligand therapy for patients whose kidneys are already compromised, and it underscores the value of extended follow-up in understanding the durability of organ safety after targeted radiation treatment. Taken together, the nine studies sketch a field that is maturing on multiple fronts at once, refining the chemistry of tracers, the timing of scans, the interpretation of images, and the measurement of long-term consequences, all in service of imaging and treating disease at the level of individual molecules and individual patients.

Subject of Research: Advances in nuclear medicine and molecular imaging reported in The Journal of Nuclear Medicine

Article Title: The Journal of Nuclear Medicine ahead-of-print tip sheet: October 9, 2026

Article References: The Journal of Nuclear Medicine ahead-of-print tip sheet: October 9, 2026. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: nuclear medicine, PET, theranostics, prostate cancer, PSMA, breast cancer, nectin-4, ischemic stroke, type 1 diabetes, neuroblastoma, hyperparathyroidism, radiopharmaceutical therapy